See more : Redeia Corporación, S.A. (REE.VI) Income Statement Analysis – Financial Results
Complete financial analysis of Lexeo Therapeutics, Inc. Common Stock (LXEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexeo Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Onano Industrial Corp. (6405.TW) Income Statement Analysis – Financial Results
- Man Wah Holdings Limited (MAWHF) Income Statement Analysis – Financial Results
- myFreightWorld Technologies, Inc. (MYFT) Income Statement Analysis – Financial Results
- Almaden Minerals Ltd. (AAU) Income Statement Analysis – Financial Results
- Takamisawa Co., Ltd. (5283.T) Income Statement Analysis – Financial Results
Lexeo Therapeutics, Inc. Common Stock (LXEO)
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 0.00 | 654.00K | 1.66M | 518.48K |
Cost of Revenue | 1.84M | 1.15M | 13.41K | 0.00 |
Gross Profit | -1.84M | -491.00K | 1.64M | 518.48K |
Gross Profit Ratio | 0.00% | -75.08% | 99.19% | 100.00% |
Research & Development | 53.13M | 49.16M | 45.12M | 4.32M |
General & Administrative | 15.38M | 12.00M | 7.17M | 787.50K |
Selling & Marketing | -1.84M | 0.00 | 0.00 | 0.00 |
SG&A | 13.54M | 12.00M | 7.17M | 787.50K |
Other Expenses | 0.00 | -2.00K | -155.00 | 4.24K |
Operating Expenses | 66.67M | 61.16M | 52.29M | 5.11M |
Cost & Expenses | 68.51M | 61.16M | 52.29M | 5.11M |
Interest Income | 2.87M | 1.33M | 15.00K | 0.00 |
Interest Expense | 205.00K | 91.00K | 0.00 | 147.15K |
Depreciation & Amortization | 1.84M | 1.15M | 13.41K | 4.24K |
EBITDA | -66.67M | -58.04M | -50.62M | -4.58M |
EBITDA Ratio | 0.00% | -8,874.77% | -3,054.25% | -884.04% |
Operating Income | -68.51M | -60.51M | -50.64M | -4.59M |
Operating Income Ratio | 0.00% | -9,252.14% | -3,055.94% | -884.86% |
Total Other Income/Expenses | 2.12M | 1.23M | 15.00K | -565.00K |
Income Before Tax | -66.39M | -59.28M | -50.62M | -5.15M |
Income Before Tax Ratio | 0.00% | -9,063.76% | -3,055.04% | -993.83% |
Income Tax Expense | 0.00 | 89.00K | -155.00 | 147.15K |
Net Income | -66.39M | -59.28M | -50.62M | -5.15M |
Net Income Ratio | 0.00% | -9,063.76% | -3,055.04% | -993.83% |
EPS | -2.49 | -2.40 | -2.05 | -0.21 |
EPS Diluted | -2.49 | -2.40 | -2.05 | -0.21 |
Weighted Avg Shares Out | 26.65M | 24.67M | 24.67M | 24.67M |
Weighted Avg Shares Out (Dil) | 26.65M | 24.67M | 24.67M | 24.67M |
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Source: https://incomestatements.info
Category: Stock Reports